SDG 3. GOOD HEALTH & WELL-BEING Exscientia

SoftBank leads funding that could net up to $525M for Exscientia’s AI drug platform

April 29, 2021, by Amirah Al Idrus

SoftBank leads funding that could net up to $525M for Exscientia’s AI drug platform aalidrus Wed, 04/28/2021 – 09:35

Read more on FierceBiotech


SDG 3. GOOD HEALTH & WELL-BEING Exscientia

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

April 12, 2021, by Business Wire Technology News

OXFORD, England–(BUSINESS WIRE)–Exscientia, a leading artificial intelligence (AI)-driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a ...

Read more on Business Wire Technology News


SDG 3. GOOD HEALTH & WELL-BEING Exscientia

5 Q’s for Garry Pairaudeau, Chief Technology Officer of Exscientia

March 11, 2021, by Christophe Carugati

The Center for Data Innovation spoke with Garry Pairaudeau, chief technology officer of Exscientia, a UK-based firm using AI for drug discovery. Pairaudeau discussed how ...

Read more on Center for Data Innovation


SDG 3. GOOD HEALTH & WELL-BEING Exscientia

BlackRock powers Exscientia to $100M series C round to fund autonomous drug design – FierceBiotech

March 5, 2021, by artificial intelligence - Google News

BlackRock powers Exscientia to $100M series C round to fund autonomous drug design  FierceBiotech

Read more on artificial intelligence - Google News


SDG 3. GOOD HEALTH & WELL-BEING Exscientia

Oxford-based Exscientia uses AI to accelerate delivery of new treatments; gets €3.44M from Gates Foundation

February 16, 2021, by Editorial team

Oxford-based leading pharmatech company Exscientia deploys Artificial Intelligence to drive drug discovery. It is claimed to be a pioneer in using AI to design a ...

Read more on Silicon Canals


SDG 3. GOOD HEALTH & WELL-BEING DRUG DISCOVERY Exscientia

Exscientia, University of Oxford partner to develop medicines targeting neuroinflammation to treat Alzheimer’s disease

February 12, 2021, by www.PharmaBiz.com

Exscientia, a leading AI drug discovery company, has announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK─ODDI) to develop ...

Read more on www.PharmaBiz.com


HEALTH & WELL BEING DRUG DISCOVERY STARTUP Exscientia

AI Drug Company Exscientia Raises $60 Million in Series C Funding 

May 26, 2020, by Alex McFarland

The British AI drug development company Exscientia has raised $60 million in a Series C financing round. It was led by Denmark’s Novo Holdings, which ...

Read more on Unite.AI